HER-Vaxx (IMU-131)
HER-2/neu positive gastric & gastroesophageal junction cancer
Phase 2bActive
Key Facts
Indication
HER-2/neu positive gastric & gastroesophageal junction cancer
Phase
Phase 2b
Status
Active
Company
About Imugene
Imugene is focused on developing next-generation immunotherapies that aim to stimulate the body's immune system to fight cancer. Its core technology platforms include oncolytic virotherapy (CF33), B-cell immunotherapy (HER-Vaxx), and checkpoint inhibitor therapies. The company has multiple candidates in clinical development, primarily targeting gastrointestinal cancers and other solid tumors, and operates through strategic collaborations with leading cancer research institutions.
View full company profile